Literature DB >> 13071

Purification and properties of a heat-stable glucocerebrosidase activating factor from control and Gaucher spleen.

S P Peters, P Coyle, C J Coffee, R H Glew.   

Abstract

Gaucher's disease is a lysosomal storage disease caused by a deficiency in the enzyme glucocerebrosidase. A small, heat-stable glycoprotein first obtained from Gaucher spleen (Ho, M. W., and O'Brien, J. S. (1971) Proc. Natl. Acad. Sci. U. S.A. 68, 2810-2813) has been observed to stimulate the activity of glucocerebrosidase isolated from normal tissue. It has been suggested that this material might be important in the physiological catabolism of glucocerebroside in normal individuals (Ho, M. W. (1974) in Enzyme Therapy in Lysosomal Storage Diseases (Tager, J. M., Hooghwinkel, G. J. M., and Daems, W. Th., eds) pp.239-246, North-Holland Publishing Co., Amsterdam). In order to investigate this suggestion, glucocerebrosidase activating factors were isolated and purified from control and Gaucher spleen and characterized. Although approximately the same mass of activator was isolated from both spleens, the two activators differ from one another in a number of important respects: (a) the activator from the control spleen is only 6 per cent as active (on a protein basis) as the activator from Gaucher spleen; (b) the amino acid compositions of the purified activators are significantly different; and (c) carbohydrate analysis of the purified activators indicates that the activator from Gaucher spleen is a glycoprotein, while that from control spleen is not. Comparative kinetic studies demonstrate that the anionic detergent, sodium taurocholate, and the acidic phospholipid, phosphatidylinositol, both stimulate glucocerebrosidase activity to a larger extent than the activator substance from Gaucher spleen. The activator from Gaucher spleen and human liver glucocerebrosidase both appear to contain significant hydrophobic character. We conclude that the activator is probably not physiologically important in the catabolism of glucocerebroside in normal tissues. The significance of the occurrence of this apparently unique glycoprotein activator in Gaucher spleen remains obscure; however, its presence represents another interesting aspect of Gaucher's disease that warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 13071

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Evidence for two cDNA clones encoding human GM2-activator protein.

Authors:  S Nagarajan; H C Chen; S C Li; Y T Li; J M Lockyer
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

2.  Assignment of the gene for human sphingolipid activator protein-2 (SAP-2) to chromosome 10.

Authors:  S Fujibayashi; F T Kao; C Jones; H Morse; M Law; D A Wenger
Journal:  Am J Hum Genet       Date:  1985-07       Impact factor: 11.025

Review 3.  Binding interactions of glycoproteins with lectins.

Authors:  J T Dulaney
Journal:  Mol Cell Biochem       Date:  1978-10-13       Impact factor: 3.396

4.  Saposin A: second cerebrosidase activator protein.

Authors:  S Morimoto; B M Martin; Y Yamamoto; K A Kretz; J S O'Brien; Y Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

5.  Gaucher disease: isolation and comparison of normal and mutant glucocerebrosidase from human spleen tissue.

Authors:  P G Pentchev; R O Brady; H E Blair; D E Britton; S H Sorrell
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

6.  Analysis of the multiple forms of Gaucher spleen sphingolipid activator protein 2.

Authors:  B C Paton; A Poulos
Journal:  Biochem J       Date:  1988-08-15       Impact factor: 3.857

7.  Effects of calcium on phosphatidylserine- and saposin C-stimulated glucosylceramide beta-glucosidase activity.

Authors:  E M Prence
Journal:  Biochem J       Date:  1995-09-01       Impact factor: 3.857

8.  Presence of activator proteins for the enzymic hydrolysis of GM1 and GM2 gangliosides in normal human urine.

Authors:  Y T Li; I A Muhiudeen; R DeGasperi; Y Hirabayashi; S C Li
Journal:  Am J Hum Genet       Date:  1983-07       Impact factor: 11.025

9.  Gaucher disease--Norrbottnian type. I. General clinical description.

Authors:  S Dreborg; A Erikson; B Hagberg
Journal:  Eur J Pediatr       Date:  1980-03       Impact factor: 3.183

Review 10.  Sphingolipid activator protein deficiency in a 16-week-old atypical Gaucher disease patient and his fetal sibling: biochemical signs of combined sphingolipidoses.

Authors:  K Harzer; B C Paton; A Poulos; B Kustermann-Kuhn; W Roggendorf; T Grisar; M Popp
Journal:  Eur J Pediatr       Date:  1989-10       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.